- Home
- ASH vs CNTA Comparison
ASH vs CNTA Comparison
Compare ASH & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASH
- CNTA
- Stock Information
- Founded
- ASH 1924
- CNTA 2020
- Country
- ASH United States
- CNTA United Kingdom
- Employees
- ASH N/A
- CNTA N/A
- Industry
- ASH Specialty Chemicals
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- ASH Consumer Discretionary
- CNTA Health Care
- Exchange
- ASH Nasdaq
- CNTA Nasdaq
- Market Cap
- ASH 2.2B
- CNTA 2.3B
- IPO Year
- ASH N/A
- CNTA 2021
- Fundamental
- Price
- ASH $52.01
- CNTA $29.06
- Analyst Decision
- ASH Buy
- CNTA Strong Buy
- Analyst Count
- ASH 8
- CNTA 9
- Target Price
- ASH $60.14
- CNTA $34.13
- AVG Volume (30 Days)
- ASH 921.4K
- CNTA 2.3M
- Earning Date
- ASH 11-04-2025
- CNTA 11-05-2025
- Dividend Yield
- ASH 3.21%
- CNTA N/A
- EPS Growth
- ASH N/A
- CNTA N/A
- EPS
- ASH N/A
- CNTA N/A
- Revenue
- ASH $1,824,000,000.00
- CNTA $15,000,000.00
- Revenue This Year
- ASH $3.18
- CNTA N/A
- Revenue Next Year
- ASH $3.72
- CNTA N/A
- P/E Ratio
- ASH N/A
- CNTA N/A
- Revenue Growth
- ASH N/A
- CNTA 118.88
- 52 Week Low
- ASH $45.21
- CNTA $9.60
- 52 Week High
- ASH $80.94
- CNTA $29.90
- Technical
- Relative Strength Index (RSI)
- ASH 57.52
- CNTA 67.70
- Support Level
- ASH $48.00
- CNTA $27.47
- Resistance Level
- ASH $51.19
- CNTA $29.33
- Average True Range (ATR)
- ASH 1.67
- CNTA 1.86
- MACD
- ASH 0.09
- CNTA 0.37
- Stochastic Oscillator
- ASH 74.23
- CNTA 89.66
About ASH Ashland Inc.
Ashland Inc is a world-wide specialty materials company that serves a wide range of industrial markets. The company has a business-centric operating model and is organized into four distinct segments: life sciences, personal care, specialty additives, and intermediates. Key customers for the firm include pharmaceutical companies and manufacturers of personal care products, food and beverages, and nutraceuticals and supplements. The life sciences segment derives maximum revenue. The company generates its sales from North America, Europe, Asia Pacific, and Latin America, and Others.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.